titanium
titanium

Titanium:
biocompatibility, durability and cost-efficiency continue to improve

By Kim Crabtree

Titanium has become a vital material in modern medicine due to its strength, light weight, corrosion resistance, and exceptional biocompatibility with high long-term success rates and minimal risk of rejection. Its non-ferromagnetic nature makes it MRI-safe, and its durability supports better healing outcomes compared to materials like stainless steel. Though more expensive, titanium’s costs are becoming more manageable, and demand is expected to surge with the aging population. Innovations like beta-titanium alloys, surface treatments, and 3D-printed implants continue to expand its medical potential.

Continue reading

Interoperability
Interoperability

What’s Missing in MedTech Innovation? The Journey Toward Plug-and-Play Device Interoperability

By Dr. Charles Jaffe, Todd Cooper

For over four decades, the medical device industry has wrestled with fragmented data exchange and proprietary integrations. HL7’s Device Interoperability FHIR Accelerator initiative offers a vendor-neutral framework to finally achieve plug-and-play interoperability—unlocking scalable, AI-powered MedTech innovation and improving patient outcomes.

Continue reading

Wearables, adhesives
Wearables, adhesives

Beyond Innovation:
Confronting the Complex Risks in Health Technology Development

By Justin Kozak

Wearables are changing the game for health monitoring. From smartwatches and rings to skin patches, glasses, and even bras, companies are in a race to bring the latest innovations to market. But as this trend gains momentum and competition heats up, so do concerns about potential risks like data privacy, cybersecurity vulnerabilities, and the possibility of inaccurate health readings that could critically impact user safety.

Continue reading

PFAS
PFAS

No Longer “Forever Chemicals”

By Dr. Christina Reufsteck

Because of the environmental and health risks that PFAS ─ per- and polyfluoroalkyl substances ─ pose, they are subject to a potential ban across the European Union. Such a ban would introduce a need for medical device manufacturers to identify and discontinue the sale of products containing PFAS, while also developing safe and effective alternatives. How will suppliers across the EU approach the impending shift away from these “forever chemicals”?

Continue reading